Eli Lilly and Company (LLY) – Revenue growth of 52% from core business in Q1FY21

The company announced new data from the randomized, double blind, placebo controlled BLAZE 1 Phase 3 study, demonstrating bamlanivimab and etesevimab together reduced COVID 19 related hospitalizations and deaths by 87 percent in high risk patients recently diagnosed with COVID 19.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 38